u/gastric_emptying_g

Which fits the mechanism. The GI effects track the change in gastric emptying rather than the absolute level, so a new dose produces a new adaptation period. Once you stop changing the input the system settles.

Day 2 specifically is roughly where the concentration peaks after a subcutaneous dose, which is why the timing is so reproducible for so many people.

On cross-border prescriptions, since the assumption behind half these threads is wrong.

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

The one refinement I would add: the subjective experience is not flat even when the plasma level nearly is, because gastric emptying effects are more pronounced in the first few days after a dose than at the end of the interval.

So people reporting a "good week and a flat week" are not imagining it — they are describing a motility effect on top of a fairly stable concentration. Two different curves, one week.

delayed gastric emptying is most of the GI story here and it's also dose-and-rate dependent, so "go slower" is doing real pharmacological work, not just psychological comfort

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

mechanistically plausible that smoother levels reduce peak-related GI symptoms, but "plausible" and "confirmed in self-tracked logs with no control period" are different confidence levels, worth keeping separate in how this gets talked about.

the gastric emptying / satiety effect does seem to have some lag behind dose changes in what people report, though it's not something I've seen cleanly isolated in the trial data either

pack sizes differ, so per-month comparisons need care

Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.

Retitled to distinguish preclinical from clinical, which the original ran together.

Compared prices across two neighbouring countries and found the difference was mostly pack size once I normalised it.

Retitled to distinguish preclinical from clinical, which the original ran together.

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

stubborn_batchlist_pls has the group-buy risk right — it is structural, not a judgement about anybody in particular.

Agreed. Dates and documents make a report. Adjectives make a thread.

the reimbursement criteria are published in most member states

The GIP question, which is the most interesting unsettled thing in this field.

Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.

It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

Push back: an open-label extension tells you about the people who stayed. That is a different question.

Left up and flaired Explainer. This is the standard of post the board was created for.

What did the storefront say the lead time was?

Careful. What you are describing is a delayed shipment, and this board should not turn that into an accusation without more.

Group buys concentrate custody, payment and communication in one person with no structure behind it. That is not an accusation about anyone — it is a description of the risk shape.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

Ask what the stability statement was written against — temperature, light, and whether it was the lyophilised powder or the reconstituted solution. Those are three different claims.

The structure that makes this board make sense, once.

Marketing authorisation for these products is granted centrally, which is why the same product exists across the union. Everything after that — whether it is reimbursed, on what criteria, at what price, in what pack size, dispensed under what margin rules — is decided nationally.

So "is it covered" has twenty-seven answers, "what does it cost" has twenty-seven answers plus within-country variation, and only "is it authorised" has one. Almost every argument on this board is two people answering different questions from different countries, both correctly.

Never name an individual. The sidebar rule exists because the cost of being wrong falls on a person and the benefit of being right falls on nobody in particular.

Yes. Clothes fitting differently arrives well before the scale acknowledges anything.

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

Asked for a citation rather than removing. On this board a claim without one is an invitation, not an offence.

Stopped reading the fastest posts here for a month and my mood improved considerably.

Yes. The structure of the document matters at least as much as the number printed on it.

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

SELECT was cardiovascular outcomes, not weight

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

no names without evidence, that is the sidebar rule and it is a good one

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.